Search clinical trials for: bias

Total 517 results

Novo Nordisk A/S

Completed

Observational Safety Study in Subjects With Type 2 Diabetes Mellitus Starting or Switching to Biphasic Insulin Aspart 30 Treatment

Diabetes Mellitus, Type 2 | Diabetes

Denmark
Novo Nordisk A/S

Completed

Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Frequency of Episodes of Hypoglycaemia During Treatment With Biphasic Insulin Aspart 30 in Type 2 Diabetes (REACH)

Diabetes Mellitus, Type 2 | Diabetes

United Kingdom
Novo Nordisk A/S

Completed

Basal Bolus of Insulin Aspart Including Insulin NPH and Biphasic Insulin Aspart in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany, Poland, Russian Federation, Spain, Sweden, Netherlands, Singapore, Malaysia, France, Croatia, Romania, United Kingdom, Hong Kong
Novo Nordisk A/S

Completed

Observational Study of Biphasic Insulin Aspart 30 Alone or in Combination With Oral Hypoglycaemic Agents in Subjects With Type 2 Diabetes (PRESENT)

Diabetes Mellitus, Type 2 | Diabetes

Korea, Republic of
Novo Nordisk A/S

Completed

Efficacy and Safety of Biphasic Insulin Aspart 30 in Combination With Metformin in Type 2 Diabetes (EUROMIX)

Diabetes Mellitus, Type 2 | Diabetes

Austria, Hungary, Slovenia, Germany, Czech Republic, Poland, Slovakia
Novo Nordisk A/S

Completed

Effect of Biphasic Insulin Aspart 30 on Blood Glucose Control in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Russian Federation
Novo Nordisk A/S

Completed

Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen® in Insulin Naive Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Former Serbia and Montenegro
Novo Nordisk A/S

Completed

Bioequivalence of Two Formulations of Biphasic Insulin Aspart 70 in Healthy Subjects

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30 and Insulin Glargine and Insulin Glulisine Therapy in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 50 to Biphasic Insulin Aspart 70 in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Denmark
Novo Nordisk A/S

Completed

Reliability of Dosing With NovoLog® Mix 70/30 FlexPen® Compared With Vial and Syringe

Diabetes Mellitus, Type 2 | Diabetes | Delivery Systems

United States
Novo Nordisk A/S

Completed

Pharmacokinetics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Denmark
Novo Nordisk A/S

Completed

Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and 50 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Glycaemic Control of Biphasic Insulin Aspart 70 and 30 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United Kingdom
Novo Nordisk A/S

Completed

Comparison of Biphasic Insulin Aspart 70/30, 50/50, and 30/70 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Poland, United Kingdom, Spain, Denmark, France, Netherlands, Austria, Hungary, Russian Federation, Germany, Turkey, Italy, Bulgaria, Romania, Belgium, Switzerland, Slovenia, Czech Republic
Novo Nordisk A/S

Completed

Pharmacokinetics of Biphasic Insulin Aspart 50 and 70 in Japanese Healthy Volunteers

Healthy | Diabetes

Japan
Novo Nordisk A/S

Completed

Comparison of Single Dose and Steady State Pharmacodynamics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Comparison of Two Biphasic Insulin Aspart Treatments in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Denmark
Novo Nordisk A/S

Completed

Comparison of Biphasic Insulin Aspart (30, 50 and 70) and Insulin Aspart in Healthy Subjects

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

Comparison of Biphasic Human Insulin 30 With Biphasic Insulin Aspart in Subjects With Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

United Kingdom, France, Netherlands, Belgium, Ireland
Universitaire Ziekenhuizen KU Leuven
KU Leuven

Completed

Oxytocin and Attachment-related Interpretation Bias

Trust

Belgium
Umeå University

Completed

Treatment of Social Phobia With Cognitive Bias Modification

Social Phobia

Sweden
Umeå University

Completed

Treatment of Social Phobia With Combined Cognitive Bias Modification and iCBT (SOFIE13a)

Social Phobia

Sweden
Umeå University

Completed

Attention Bias Modification Training in Social Phobia/Social Anxiety Disorder (SOFIE-11)

Social Phobia

Sweden
Novo Nordisk A/S

Completed

Observational Study to Observe the Safety of NovoMix® 30 Treatment in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Norway, Sweden
Novo Nordisk A/S

Completed

An Observational Study to Compare the Safety and Effectiveness of NovoMix® 30 and Levemir™ for the Treatment of Diabetes (SAFE)

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Philippines
Novo Nordisk A/S

Completed

Safety of Treatment Initiation With Biphasic Insulin Aspart 30 in Hospitalised Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Poland
Novo Nordisk A/S

Completed

Effect of Biphasic Insulin Compared to Biphasic Insulin Combined With Insulin Aspart, With or Without Metformin in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Saudi Arabia, Egypt
Novo Nordisk A/S

Completed

Observational Study on Safety and Efficacy of Biphasic Insulin Aspart in Type 2 Diabetes Patients

Diabetes Mellitus, Type 2 | Diabetes

Israel
Novo Nordisk A/S

Completed

Observational Study to Assess the Quality of Life and Clinical Outcomes in Subjects Using NovoMix® 30 for the Treatment of Diabetes (IMPROVE Life)

Diabetes Mellitus, Type 2 | Diabetes

India
Novo Nordisk A/S

Completed

Observational Study to Evaluate the Efficacy and Safety of NovoMix® 30 in Type 1 and 2 Diabetes (EFFECTIVE)

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Former Serbia and Montenegro
Novo Nordisk A/S

Completed

Observational Study on Blood Glucose Control in Patients With Diabetes Using Modern Insulin (COMMIT)

Diabetes Mellitus, Type 2 | Diabetes

Slovakia
Novo Nordisk A/S

Completed

Observational Study of NovoMix® 50 for Treatment of Type 2 Diabetics for 12 Months

Diabetes Mellitus, Type 2 | Diabetes

Slovenia
Novo Nordisk A/S

Completed

Observational Study on Efficacy and Safety in Patients Using NovoMix® 30 for the Treatment of Diabetes (UPGRADE)

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Korea, Republic of
University of Wisconsin, Milwaukee

Terminated

Interpretive Biases in Children With Social Anxiety

Social Anxiety | Social Anxiety Disorder

United States
Turning Point
Monash University; Deakin University

Completed

Can Cognitive-bias Modification Training During Inpatient Alcohol Detoxification Reduce Relapse Rates Post-discharge?

Alcohol Dependence

Australia
University of Missouri-Columbia
National Cancer Institute (NCI)

Completed

The Psychosocial Effect of Thoughts of Personal Mortality on Cardiac Risk Assessment by Medical Students

Prejudice

United States
Universitätsklinikum Hamburg-Eppendorf

Completed

A Trial on Metacognitive Training for Depression (D-MCT)

Depression

Germany
Florida State University

Completed

Computerized Anxiety Treatment for Suicide (CATS)

Anxiety | Suicide

United States
AHS Cancer Control Alberta

Completed

Biological Investigations in Active Surveillance (BIAS) IGAR 2008 I 19 in Prostate Cancer Using High Field MRI (3 Tesla), PET, and Biomarkers

Prostate Cancer

Canada
Florida State University

Completed

Computerized Cognitive Bias Intervention for Intolerance of Uncertainty

Intolerance of Uncertainty; Anxiety

United States
University of Washington

Completed

Testing for the Presence of Authorship Bias in Peer Review

Peer Review
Novo Nordisk A/S

Completed

Effect of Biphasic Insulin Aspart 30 Combined With Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin

Diabetes Mellitus, Type 2 | Diabetes

China
Federal University of Minas Gerais

Completed

Nutritional Intervention in Migraine

Migraine

Brazil
Novo Nordisk A/S

Completed

Prandial Orientated Biphasic Insulin Aspart 30 Therapy - the Physiological Premix Insulin Therapy for Type 2 Diabetes (ProMix)

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Observational Study to Evaluate the Safety of NovoMix® 30 FlexPen®

Diabetes Mellitus, Type 2 | Diabetes

Tunisia
Novo Nordisk A/S

Completed

Post Marketing Surveillance Study of Biphasic Insulin Aspart 30

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Korea, Republic of
Novo Nordisk A/S

Completed

Special Survey for Patients With Type 1 or Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Paediatric Subjects - Special Survey

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Japan

3

Subscribe